Skip to Main Content
Home Books Internal Medicine: A Guide to Clinical Therapeutics

Chapter 8. Pulmonary Arterial Hypertension (PAH)

Rebecca L. Attridge; Rebecca Moote; Deborah J. Levine

  • Sections
  • Print
  • Get Citation

    Citation

    AMA Citation
    Attridge RL, Moote R, Levine DJ. Attridge R.L., Moote R, Levine D.J. Attridge, Rebecca L., et al.Chapter 8. Pulmonary Arterial Hypertension (PAH). In: Attridge RL, Miller ML, Moote R, Ryan L. Attridge R.L., Miller M.L., Moote R, Ryan L Eds. Rebecca L. Attridge, et al.eds. Internal Medicine: A Guide to Clinical Therapeutics New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com/content.aspx?bookid=565&sectionid=42003716. Accessed November 20, 2019.
    MLA Citation
    Attridge RL, Moote R, Levine DJ. Attridge R.L., Moote R, Levine D.J. Attridge, Rebecca L., et al.. "Chapter 8. Pulmonary Arterial Hypertension (PAH)." Internal Medicine: A Guide to Clinical Therapeutics Attridge RL, Miller ML, Moote R, Ryan L. Attridge R.L., Miller M.L., Moote R, Ryan L Eds. Rebecca L. Attridge, et al. New York, NY: McGraw-Hill, 2013, http://accesspharmacy.mhmedical.com/content.aspx?bookid=565&sectionid=42003716.

    Download citation file:

    RIS (Zotero)
    EndNote
    BibTex
    Medlars
    ProCite
    RefWorks
    Reference Manager
    Mendeley
    © Copyright
  • Tools
  • Search Book
  • Clip
Top

  • Clinical pathological definition: vasculopathy of the small pulmonary arteries which leads to ↑ pulmonary vascular resistance; may progress to right heart dysfunction & failure
  • Hemodynamic definition: mean pulmonary artery pressure (mPAP) ≥25mmHg at rest, AND pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15mmHg measured by right heart catheterization
  • Established disease mediators: endothelin-1, prostacyclin, nitric oxide (J Am Cardiol 2009;53:1573)

Figure 8-1.
image
View Full Size|Favorite Figure|Download Slide (.ppt)
image

Pulmonary arterial hypertensionpathophysiology. BMPR-2: bone morphogenetic protein receptor II; ALK1: activin receptor-like kinase 1; HTT: hydroxytryptamine transporter; ec-NOS: nitric oxide synthase; CPS: carbamyl phosphate synthase.

WHO Functional Classification of PAH

Table 8-1 WHO Functional Classification of Pulmonary Arterial Hypertension
View Table|Favorite Table|Download (.pdf)
Table 8-1 WHO Functional Classification of Pulmonary Arterial Hypertension

Class

Description

I

Patients with PAH in whom there is NO limitation of usual physical activity; ordinary physical activity does NOT cause increased dyspnea, fatigue, chest pain, or presyncope

II

Patients with PAH who have mild limitation of physical activity; there is NO discomfort at rest, but normal physical activity causes increased dyspnea, fatigue, chest pain, or presyncope

III

Patients with PAH who have marked limitation of physical activity; there is NO discomfort at rest, but less than normal physical activity causes increased dyspnea, fatigue, chest pain, or presyncope

IV

Patients with PAH who are unable to perform any physical activity at rest & who may have signs of right ventricular failure; dyspnea, &/or fatigue may be present at rest, & symptoms are increased by almost any physical activity

Etiology of PAH

(Group 1 of WHO Pulmonary Hypertension Classification) (J Am Cardiol 2009;53:1573)

  • Idiopathic (IPAH)
  • Heritable (BMPR2, ALK1, endoglin, unknown)
  • Drug or toxin-induced: fenfluramine, cocaine, toxic rapeseed oil
  • Associated with (APAH): connective tissue diseases, HIV infection, portal hypertension, congenital heart diseases, schistosomiasis, chronic hemolytic anemia
  • Persistent pulmonary hypertension of the newborn
  • Pulmonary veno-occlusive disease (PVOD) &/or pulmonary capillary hemangiomatosis (PCH)

Prognosis:

Dependent on WHO Functional Class, Hemodynamics, & Etiology of PAH

  • Diagnosis made hemodynamically by right heart catheterization (RHC) (Circulation 2006;114;1417)
    • Establishes diagnosis & guides treatment decisions
    • Evaluates pulmonary vasoreactivity
      • Use fast-acting, short-duration vasodilators (ex: epoprostenol, nitric oxide, adenosine) to determine extent of vasodilator response
      • Positive response: reduction of mPAP by at least 10mmHg to a value of 40mmHg or less; ↑ or unchanged CO
      • Negative response: should never receive trial of calcium channel blockers; move to PAH targeted therapy
  • Echocardiography: assess right heart function & right-sided chamber size, estimate pulmonary pressures; used primarily as screening tool & helpful in ruling out other cardiac processes
  • Evaluation of etiology of PAH: HIV test, serologies for connective tissue diseases, hepatitis panel, thyroid function tests, pulmonary function tests (to evaluate for restrictive or obstructive lung disease), evaluation for chronic ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close